[Beneficial effects of statins and angiotensin converting enzyme inhibitors on aggregability of red blood cells in hypertensive patients].
This study was designed to investigate changes in aggregability of red blood cells of patients with essential hypertension and concomitant hypercholesterolemia (total cholesterol level > 5.0 mmol/l) following the use of angiotensin converting enzyme inhibitors (ACE-I) along with or without inhibitor of reductase HMG-CoA (statin). Under standard pharmacotherapy (beta-receptor anatgonist, calcium chanel antagonist, and diuretic) aggregability of RBC in hypertensive patients was significantly increased in spite of the treatment. However, in patients receiving additionally ACE-I spontaneous aggregation of RBC was attenuated. We found that antihypertensive therapy consisting of ACE-I along with statin improved erythrocyte aggregation nearly to the level of normotensive and normocholesterolemic patients. Interestingly, this improvement of blood rheology was observed prior to statin-induced lowering of total cholesterol.
Korbut
Renata Angelika
RA
Katerdra I Klinika Chorób Wewnetznych I Medycyny Wsi Collegium Medicum Uniwersytetu Jagielloriskiego, Kraków. mmkorbut@cyf-kr.edu.pl
Guzik
Bartłomiej
B
Adamek-Guzik
Teresa
T
Korbut
Ryszard
R
D000293:Adolescent; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage; D001241:Aspirin / Q000009:adverse effects; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004903:Erythrocyte Aggregation / Q000187:drug effects*; D004907:Erythrocyte Deformability / Q000187:drug effects; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006937:Hypercholesterolemia / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D006973:Hypertension / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D001241:Aspirin